Clinical Trial Update: Study Comparing 3 Formulations to Evaluate the Efficacy and Safety of the Inflammatory Symptoms of the Upper Respiratory Tract, in Children Between 2 and 6 Years Old [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating three formulations for inflammatory symptoms of the upper respiratory tract in children aged 2 to 6 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Cold

Drugs mentioned

• Formulation 1
• Formulation 2
• Formulation 3

Snippet

Sponsor: Ache Laboratorios Farmaceuticos S.A. | Conditions: Common Cold | Phase 3 | Status: WITHDRAWN